5 Biggest Diet/Weight Loss Companies in the World

3. Amgen, Inc. (NASDAQ:AMGN)

Estimated Valuation as of December 11: $148.68 billion

Amgen, Inc. (NASDAQ:AMGN) is a biotech company based in Thousand Oaks, California. In the weight loss sector, the company’s weight-loss hormone, Leptin, has been incredibly successful in helping dieters control their appetite and manage their weight.

On December 13, Christopher Raymond at Piper Sandler reiterated an Overweight rating on Amgen, Inc. (NASDAQ:AMGN) shares.

Amgen, Inc. (NASDAQ:AMGN) had a net income of $5.89 billion and revenues of $25.98 billion as of 2021. By 2020, the company had about 24,300 employees.

Smead Capital Management, an investment management company, mentioned Amgen, Inc. (NASDAQ:AMGN) in its third-quarter 2022 investor letter. Here’s what the firm said:

“Two things are very noticeable right off the top. First, sometimes you have to be happy losing less in a bear market environment so that you have more of your capital to grow in the next bull market. We are never really happy losing money. Second, 2022 is likely to be our third year of existence as a fund to lose money for the year. This year would join 2008 and 2018 in this undistinguished category. Our biggest detractors was dominated by  Amgen (NASDAQ:AMGN). Consumer/investor fears about media and e-commerce hit WBD and EBAY and profit taking in Amgen came from early 2022 strength.”